New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Team explores anti-breast cancer properties of soy

Team explores anti-breast cancer properties of soy

by University of ArizonaOrnella I. Selmin, PhD (left), and Donato F. Romagnolo, PhD (right). Credit: University of Arizona Cancer CenterA University of Arizona Cancer Center research team is enga
Oncology May 27,2024
Team explores anti-breast cancer properties of soy

Team explores anti-breast cancer properties of soy

by University of ArizonaOrnella I. Selmin, PhD (left), and Donato F. Romagnolo, PhD (right). Credit: University of Arizona Cancer CenterA University of Arizona Cancer Center research team is enga
Oncology May 27,2024
Team targets tumor suppressor to treat 'triple-negative' breast cancer

Team targets tumor suppressor to treat 'triple-negative' breast cancer

by University of Arizona Health SciencesAgnieszka Witkiewicz, MD and Erik Knudsen, PhD, UA Cancer Center. Credit: BioCommunications, Kris HanningA study by scientists at the University of Arizona Canc
Oncology May 27,2024
Team targets tumor suppressor to treat 'triple-negative' breast cancer

Team targets tumor suppressor to treat 'triple-negative' breast cancer

by University of Arizona Health SciencesAgnieszka Witkiewicz, MD and Erik Knudsen, PhD, UA Cancer Center. Credit: BioCommunications, Kris HanningA study by scientists at the University of Arizona Canc
Oncology May 27,2024
Onions and garlic may be recipe for reducing breast cancer risk: study

Onions and garlic may be recipe for reducing breast cancer risk: study

by David J. Hill,University at BuffaloCredit: CC0 Public DomainOnions and garlic are key ingredients in sofrito, a condiment that's a staple of Puerto Rican cuisine. They may also be a recip
Oncology May 27,2024
Onions and garlic may be recipe for reducing breast cancer risk: study

Onions and garlic may be recipe for reducing breast cancer risk: study

by David J. Hill,University at BuffaloCredit: CC0 Public DomainOnions and garlic are key ingredients in sofrito, a condiment that's a staple of Puerto Rican cuisine. They may also be a recip
Oncology May 27,2024
Significant proportion of cancer drugs lack proof of added benefit, finds study

Significant proportion of cancer drugs lack proof of added benefit, finds study

by British Medical JournalCredit: CC0 Public DomainMany cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved
Oncology May 26,2024
Significant proportion of cancer drugs lack proof of added benefit, finds study

Significant proportion of cancer drugs lack proof of added benefit, finds study

by British Medical JournalCredit: CC0 Public DomainMany cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved
Oncology May 26,2024
GZ17-6.02 with bexarotene kills mycosis fungoides cells: Study

GZ17-6.02 with bexarotene kills mycosis fungoides cells: Study

by Impact Journals LLCCombined macroautophagy and CD95 death receptor signaling facilitate additional tumor cell killing by GZ17-6.02. Credit: 2024 Booth et al.A new research paper titled "GZ17-6
Oncology May 26,2024
GZ17-6.02 with bexarotene kills mycosis fungoides cells: Study

GZ17-6.02 with bexarotene kills mycosis fungoides cells: Study

by Impact Journals LLCCombined macroautophagy and CD95 death receptor signaling facilitate additional tumor cell killing by GZ17-6.02. Credit: 2024 Booth et al.A new research paper titled "GZ17-6
Oncology May 26,2024
Ketamine's promise for severe depression grows, but major questions remain

Ketamine's promise for severe depression grows, but major questions remain

by University of MichiganCredit: CC0 Public DomainUsing an old anesthesia drug to pull people out of the depths of severe depression has gone from fringe idea to widespread use in just a few year
Oncology May 26,2024
Ketamine's promise for severe depression grows, but major questions remain

Ketamine's promise for severe depression grows, but major questions remain

by University of MichiganCredit: CC0 Public DomainUsing an old anesthesia drug to pull people out of the depths of severe depression has gone from fringe idea to widespread use in just a few year
Oncology May 26,2024
Here's why some high-risk patients aren't getting drugs to combat COVID

Here's why some high-risk patients aren't getting drugs to combat COVID

by Emily Alpert Reyes, Los Angeles TimesCredit: Unsplash/CC0 Public DomainAs the toll from the COVID-19 pandemic continued to mount, antiviral medications such as Paxlovid were hailed by health offici
Oncology May 26,2024
Here's why some high-risk patients aren't getting drugs to combat COVID

Here's why some high-risk patients aren't getting drugs to combat COVID

by Emily Alpert Reyes, Los Angeles TimesCredit: Unsplash/CC0 Public DomainAs the toll from the COVID-19 pandemic continued to mount, antiviral medications such as Paxlovid were hailed by health offici
Oncology May 26,2024
Experts assess promise of vamorolone to treat Duchenne muscular dystrophy

Experts assess promise of vamorolone to treat Duchenne muscular dystrophy

by IOS PressSkeletal muscle fibers. Credit: Berkshire Community College Bioscience Image Library / Public domainThe drug vamorolone (Agamree) has been hailed as a promising new drug to treat Duch
Oncology May 26,2024
Experts assess promise of vamorolone to treat Duchenne muscular dystrophy

Experts assess promise of vamorolone to treat Duchenne muscular dystrophy

by IOS PressSkeletal muscle fibers. Credit: Berkshire Community College Bioscience Image Library / Public domainThe drug vamorolone (Agamree) has been hailed as a promising new drug to treat Duch
Oncology May 26,2024
Is cold water bad for you? What about drinking from the hose or tap? The facts behind five water myths

Is cold water bad for you? What about drinking from the hose or tap? The facts behind five water myths

by Oliver A.H. Jones,The ConversationCredit: Unsplash/CC0 Public DomainWe know theimportance of staying hydrated, especially in hot weather. But even for something as simple as a drink of
Oncology May 26,2024
Is cold water bad for you? What about drinking from the hose or tap? The facts behind five water myths

Is cold water bad for you? What about drinking from the hose or tap? The facts behind five water myths

by Oliver A.H. Jones,The ConversationCredit: Unsplash/CC0 Public DomainWe know theimportance of staying hydrated, especially in hot weather. But even for something as simple as a drink of
Oncology May 26,2024
Researchers test previously approved FDA drugs to treat Lowe syndrome

Researchers test previously approved FDA drugs to treat Lowe syndrome

by Purdue UniversityR. Claudio Aguilar, a Purdue University researcher, has developed a patented therapeutic strategy for Lowe syndrome by repurposing two drugs previously approved by the U.S. Fo
Oncology May 26,2024
Researchers test previously approved FDA drugs to treat Lowe syndrome

Researchers test previously approved FDA drugs to treat Lowe syndrome

by Purdue UniversityR. Claudio Aguilar, a Purdue University researcher, has developed a patented therapeutic strategy for Lowe syndrome by repurposing two drugs previously approved by the U.S. Fo
Oncology May 26,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com